ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Center For Molecular Medicine Among First To Offer New FDA Approved Test To Aid In Treatment Of Prostate Cancer
The Center for Molecular
Medicine (CMM) announced it is one of the first laboratories in the
nation to offer a new, FDA-approved test that will aid in the treatment of
metastatic prostate cancer.
The CMM (http://www.cmmdx.org) is offering the CellSearch(TM) System from
Veridex (http://www.veridex.com) to physicians as a vital new tool in managing
patients with metastatic prostate cancer (MPC). The CMM made CellSearch
testing services available to physicians last year to help inform treatment
of metastatic breast and colorectal cancer.
"This newest addition to our cutting-edge menu of diagnostic services
gives physicians another tool for better managing their patients' cancer,
this time prostate cancer," said CMM Executive Director Dr. Daniel H.
Farkas. "In just one year, the CMM has made available to this community
tests that detect and manage breast, colorectal and prostate cancers in a
more proactive and efficient way than has ever been possible. It's exciting
and we're pleased to serve as a unique medical resource."
The CellSearch System identifies and counts circulating tumor cells
(CTCs) in a blood sample to predict progression-free and overall-survival
in patients, and can do so earlier than the current standard of care.
Testing for CTCs with the CellSearch System, in conjunction with other
clinical methods for monitoring, can help physicians assess disease
progression, thereby guiding more informed care decisions earlier.
The CellSearch System is the first diagnostic test to automatically
identify and count CTCs, cancer cells that detach from solid tumors and
enter the bloodstream. The system's specificity, sensitivity and
reproducibility allow assessment of CTCs as early as the first cycle of
treatment to help evaluate disease progression sooner.
According to the American Cancer Society (ACS), prostate cancer is the
most common type of cancer found in American men, other than skin cancer.
The ACS estimates that there will be about 186,320 new cases of prostate
cancer in the U.S. this year, and about 28,660 men will die as a result.
MPC occurs when tumor cells spread to other locations in the body and grow.
Although there are several options for the treatment of MPC, oncologists
often have to wait months before they can determine if a specific treatment
has been beneficial to the patient.
About the CMM
The Center for Molecular Medicine, a joint venture between Grand
Rapids, Mich.-based Spectrum Health and Van Andel Institute (VAI), brings
West Michigan a cutting-edge laboratory that will aid in early diagnoses
and enhance personalized medicine. It offers 21st century molecular
technologies for investigation of complex diseases like cancer, heart
disease, mental illness and other conditions at the DNA, RNA and protein
levels. The Center brings new and increased opportunities for diagnostics
and pharmaceutical companies to conduct trials in a world-class medical and
clinical research environment. For more information, visit http://www.cmmdx.org.
The Center for Molecular Medicine
http://www.cmmdx.org
Centrul de medicinã molecularã între prima de a oferi noi FDA aprobat de test pentru a ajutor în tratamentul cancerului de prostatã - Center For Molecular Medicine Among First To Offer New FDA Approved Test To Aid In Treatment Of Prostate Cancer - articole medicale engleza - startsanatate